What's Happening?
Lotte Biologics is set to unveil its Songdo bio campus, scheduled for completion in August, at the 2026 BIO International Convention in San Diego, California. The company aims to expand partnerships with global clients by showcasing photos and videos
of Songdo Bio Campus Plant 1, highlighting its large-scale production capacity and customized manufacturing capabilities. Lotte Biologics will operate an independent exhibition booth to discuss potential business collaborations and present its vision and business capabilities. The company plans to emphasize its operational advantages connecting North America and Asia, and will host presentations on collaboration strategies, computational fluid dynamics technology, and smart manufacturing capabilities.
Why It's Important?
The unveiling of Songdo Plant 1 marks a significant milestone for Lotte Biologics as it seeks to strengthen its global contract development and manufacturing organization (CDMO) competitiveness. By showcasing its manufacturing capabilities at BIO USA, the company aims to attract potential business collaborations and expand its presence in the biotechnology industry. The strategic location of Songdo operations, connecting North America and Asia, positions Lotte Biologics to leverage its manufacturing capabilities and enhance its global reach. This development is crucial for the company's growth and its ability to meet the increasing demand for biopharmaceutical manufacturing services.
What's Next?
Lotte Biologics plans to complete the Songdo bio campus by August and formally begin its operations era. The company will continue to strengthen its CDMO competitiveness by leveraging its operational system connecting Syracuse in the US and Songdo in Korea. The presentations at BIO USA will focus on collaboration strategies, manufacturing efficiency, and digitalization, which are expected to enhance the company's manufacturing capabilities and attract global clients. Lotte Biologics' participation in the convention may lead to new partnerships and business opportunities, further solidifying its position in the biotechnology industry.
